MedTrace Logo

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

NCT07017179 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 871

Last updated 2026-04-20

No results posted yet for this study

Summary

This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.

Conditions

  • Obesity/Overweight

Interventions

DRUG

AZD6234

Participants will receive a subcutaneous injection weekly

DRUG

Placebo

Participants will receive a subcutaneous injection weekly.

DRUG

AZD9550

Participants will receive a subcutaneous injection weekly

DRUG

Plocebo

Participants will receive a subcutaneous injection weekly

DRUG

AZD6234 in combination with AZD9550

Participants will receive a subcutaneous injection weekly

DRUG

Placebo

Participants will receive a subcutaneous injection weekly

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2026-08-06
Completion
2026-08-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07017179 on ClinicalTrials.gov